SWOG clinical trial number
SWOG-8011

Evaluation of Dihydroxyanthracenedione (DHAD) in Patients with Advanced Renal Cell Carcinoma

Closed
Phase
Abbreviated Title
Evaluation of Dihydroxyanthracenedione (DHAD) in Patients with Advanced Renal Cell Carcinoma
Activated
07/02/1980
Closed
04/14/1981

Publication Information Expand/Collapse

1984

Phase II clinical trial of mitoxantrone in patients with advanced renal cell carcinoma: A Southwest Oncology Group study.

SA Taylor;DD Von Hoff;LH Baker;SP Balcerzak Cancer Treat Rep 68:919-920

1983

Southwest Oncology Group Phase II studies with Mitoxantrone in nonhematologic malignancies.

RL Stephens;DD Von Hoff;SA Taylor;WA Knight III;RB Livingston;FE Bull;J Cowan;RD Hilgers;CK Osborne;GA Gates;G Clark In: New Anticancer Drugs: Mitoxantrone and Bisantrene . M Rozencweig, et al, eds. New York: Raven Press, 125-30

Cardiotoxicity in patients treated with Mitoxantrone on Southwest Oncology Group Phase II protocols.

GM Clark;LK Tokaz;DD Von Hoff;LL Thoi;CA Coltman Jr Cancer Treat Symp 3:25-30

1982

Phase II trial of dihydroxyanthracenedione (DHAD) in advanced renal cell carcinoma: A SWOG study.

SA Taylor;DD Von Hoff ASCO #C-457

1981

Southwest Oncology Group (SWOG) Phase II with mitoxantrone in non-hematologic malignancies.

RL Stephens;G Clark 3rd NCI-EORTC Symposium on New Drugs in Cancer Therapy (October 15-17, 1981), #36